VivoSeq
Infectious Disease

Respiratory Tract Infection

66

Pipeline Programs↗

11

Active Trials↗

24

Companies Involved↗

Respiratory tract infection is a moderately active landscape with 66 programs across 24 companies. The most active players are ARS Pharmaceuticals, Inc., Ablynx, a Sanofi company, Merck & Co.. 19 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

22/100

Mech. Concentration

17/100

Completion Rate

78/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

ARS Pharmaceuticals, Inc.

1 program

Phase 1A

Ablynx, a Sanofi company

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2E

Enanta Pharmaceuticals, Inc

1 program

Phase 2Q

Qu Biologics Inc.

1 program

Phase 2A

Avalo Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical10

Clarithromycin

AbbVie

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Amoxicillin

Global Antibiotics Research and Development Partnership

Guaifenesin

Aultman Health Foundation

Echinacea

National Center for Complementary and Integrative Health (NCCIH)

Phase 16

Flurbiprofen

Pharmacia and Upjohn

Cefuroxime

Philadelphia Eye Associates

ARS-1

ARS Pharmaceuticals, Inc.

Qingfei Granule

Zhong Wang

Difflam

University of Melbourne

Phase 214

Prednisone

Roxane Laboratories

Montelukast

Organon and Co

ALX-0171

Ablynx, a Sanofi company

Remdesivir

Gilead

Symbicort

AstraZeneca

Phase 317

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Loxoprofen

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Oseltamivir

Conrado Roberto Hoffmann Filho

Broncho-Vaxom

OM Pharma SA

MEDI8897

AstraZeneca

Approved19

Levofloxacin

Wim Janssens

Acetaminophen

Kenvue Brands

Tobramycin

Viatris Specialty LLC

Meropenem

B. Braun Medical Inc.

Ibuprofen

Kenvue Brands

Analysis

Modality Breakdown

96%

Small molecule

73 of 76 classified programs — the dominant modality here.

4%ALL OTHERSVaccine23%Monoclonal antibody11%

Small molecule leads; the ring shows all 76 classified programs, each share of the total. Modality classified for 100% of 81 pipeline programs.

Analysis

Trial Status

76

clinical trials

Completed45 · 59%
Terminated8 · 11%
Unknown status7 · 9%
Withdrawn5 · 7%
Not yet recruiting4 · 5%
Recruiting4 · 5%
Other3 · 4%

Clinical Trials

Trial Activity

76 trials

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06817889·60 enrolled
Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults
Recruiting·QQu Biologics Inc.·Phase 2·NCT05421325·72 enrolled
PREDICATE Trial For Respiratory Tract Infections
Recruiting·TThe University of Hong Kong·Phase 3·NCT06472219·1,300 enrolled
Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.
Recruiting·—·Phase 3·NCT05063149·500 enrolled
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
Active, not recruiting·OOM Pharma SA·Phase 4·NCT05677763·525 enrolled
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
Active, not recruiting·RRestorbio Inc.·Phase 2·NCT03373903·652 enrolled
Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care
Not yet recruiting·FFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina·Phase 4·NCT06581367·474 enrolled
A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.
Not yet recruiting·UUniversity of Witwatersrand, South Africa·Phase 4·NCT06955728·13,000 enrolled
The Effect of Vitamin E Supplementation on Hospital Stay Duration in Non-cyanotic Heart Disease Children With Lower Respiratory Tract Infections
Not yet recruiting·—·Phase 4·NCT06926712·260 enrolled
HAIQU (Hospital AIr QUality): Breathing Life Into Patient Care
Not yet recruiting·MMayo Clinic·Preclinical·NCT07670117·850 enrolled
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
Enrolling by invitation·National Institute on Deafness and Other Communication Disorders (NIDCD)·N/A·NCT07149428·80 enrolled
Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infections
Completed·UUniversity of Melbourne·Phase 1·NCT05955885·101 enrolled
Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR
Completed·AAbbott·N/A·NCT01076153·760 enrolled
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Completed·EEnanta Pharmaceuticals, Inc·Phase 2·NCT04196101·82 enrolled
Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years
Completed·HHormozgan University of Medical Sciences·N/A·NCT01396889·100 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)